News

GAIA BioMedicine Closes JPY 1.3 Billion (USD 11.9 Million) Series B Investment to Advance the GAIA-102 Platform, The Panted “Off-The-Shelf” NK Cells Like Cell Therapy Platform, For Versatile Solid Tumors

PMDA received an application for a clinical trial for the IND package of GAIA-102 i.v.

New Funding by AMED for a Clinical Trial of GAIA-102 to Treat Malignant Ascites

Nikkei Biotech ONLINE – GAIA BioMedicine is now developing allogeneic natural killer (NK)-like cell therapy for solid tumors –

An article published in the Nihon Keizai Shimbun. – Allogeneic natural killer (NK)-like cell therapy for solid tumors –

Our President & CEO Kazu Kuramori was at the Innate Killer Summit 2019 – Title：GAIA-102 as an NK Cell-Based “Upward Compatible” Modality Over CAR-T-Cell Therapy –

GAIA BioMedicine has released an experimental kit to produce highly activated NK-like cells for research use

Nikkei Biotech ONLINE – A venture company aiming at practical application of cell medicine for cancer using NK cells –